Comparing the Ongoing Pregnancy Rate for Vitrification of Day-4 Morula With Day-5 Blast (NCT03787901) | Clinical Trial Compass
TerminatedNot Applicable
Comparing the Ongoing Pregnancy Rate for Vitrification of Day-4 Morula With Day-5 Blast
Stopped: Failed to achieve sample size due to COVID19 pandemic
Egypt53 participantsStarted 2019-01-15
Plain-language summary
Comparing the vitrification at Day-4 (morula stage) with the blastocyst stage vitrification outcomes with the transfer of all day 5 after warming seems need evaluation. To the best of our knowledge, there has been no random-controlled trial conducted such comparison. Altogether, this trial is to evaluate the morula stage vitrification to blastocyst vitrification on the ongoing pregnancy rate after ICSI.
Who can participate
Age range18 Years – 40 Years
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Women age of ≥ 18 to ≤ 40
✓. BMI of ≤ 31
✓. Normal responder (≥ 12 antral follicle count (AFC) during basal ultrasound examination) or hyper responder
✓. The freeze-all groups including PCOS, OHSS, or high Progesterone at trigger day
✓. Women who have ≥ 1 year of primary or secondary infertility
✓. Tubal factor (unilateral, bilateral obstruction or salpingectomy)
✓. Fresh semen ejaculates but not frozen or surgically retrieved sperm
✓. Male factor: oligoasthenozoospermia but not globozoospermia or pinhead sperm
Exclusion criteria
✕. Women who have uncorrectable uterine pathology or abnormality including submucous myoma
✕. Women or their husbands who have abnormal karyotyping
What they're measuring
1
The ongoing pregnancy rate
Timeframe: 12 weeks
Trial details
NCT IDNCT03787901
SponsorEgyptian Foundation of Reproductive Endocrinology